These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1987 related articles for article (PubMed ID: 29972754)
1. Chimeric Antigen Receptor Therapy. June CH; Sadelain M N Engl J Med; 2018 Jul; 379(1):64-73. PubMed ID: 29972754 [No Abstract] [Full Text] [Related]
2. Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes. Shirasu N; Kuroki M Anticancer Res; 2012 Jun; 32(6):2377-83. PubMed ID: 22641678 [TBL] [Abstract][Full Text] [Related]
3. CAR therapy: the CD19 paradigm. Sadelain M J Clin Invest; 2015 Sep; 125(9):3392-400. PubMed ID: 26325036 [TBL] [Abstract][Full Text] [Related]
4. What CAR Will Win the CD19 Race? Quintás-Cardama A Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581 [TBL] [Abstract][Full Text] [Related]
5. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy. Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197 [TBL] [Abstract][Full Text] [Related]
7. CART trials are going ahead. Wei J; Han W Sci China Life Sci; 2017 Nov; 60(11):1276-1279. PubMed ID: 29170890 [No Abstract] [Full Text] [Related]
8. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects. Di S; Li Z Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709 [TBL] [Abstract][Full Text] [Related]
9. CARTs for Solid Tumors: Feasible or Infeasible? Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Marcus A; Eshhar Z Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086 [TBL] [Abstract][Full Text] [Related]
11. CAR T-cell design: a long road ahead. The Lancet Haematology Lancet Haematol; 2018 Mar; 5(3):e95. PubMed ID: 29499769 [No Abstract] [Full Text] [Related]
13. Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You. Ruella M; June CH Curr Hematol Malig Rep; 2016 Oct; 11(5):368-84. PubMed ID: 27475429 [TBL] [Abstract][Full Text] [Related]
14. Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy. Rosenbaum L N Engl J Med; 2017 Oct; 377(14):1313-1315. PubMed ID: 28902570 [No Abstract] [Full Text] [Related]
15. Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers. Tay JC; Zha S; Wang S Immunotherapy; 2017 Dec; 9(16):1339-1349. PubMed ID: 29185393 [TBL] [Abstract][Full Text] [Related]
16. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300 [TBL] [Abstract][Full Text] [Related]
17. Finding suitable targets is the major obstacle to cancer gene therapy. Rosenberg SA Cancer Gene Ther; 2014 Feb; 21(2):45-7. PubMed ID: 24535159 [No Abstract] [Full Text] [Related]
18. Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. Leuci V; Mesiano G; Gammaitoni L; Aglietta M; Sangiolo D Curr Gene Ther; 2014 Feb; 14(1):52-62. PubMed ID: 24365144 [TBL] [Abstract][Full Text] [Related]
19. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials. Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187 [TBL] [Abstract][Full Text] [Related]
20. T-cell therapy extends cancer survival to years. Ledford H Nature; 2014 Dec; 516(7530):156. PubMed ID: 25503214 [No Abstract] [Full Text] [Related] [Next] [New Search]